Aerie Pharma (AERI) Receives a Rating Update from a Top Analyst

Mizuho Securities analyst Difei Yang maintained a Buy rating on Aerie Pharma (NASDAQ: AERI) today and set a price target of $77. The company’s shares closed on Friday at $58.45.

Yang wrote:

“We would be buyers on the back of the recent share price weakness.”

According to TipRanks.com, Yang is a top 100 analyst with an average return of 25.4% and a 55.2% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics.

Aerie Pharma has an analyst consensus of Strong Buy, with a price target consensus of $86.33.

See today’s analyst top recommended stocks >>

Based on Aerie Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $55.02 million. In comparison, last year the company had a GAAP net loss of $28.43 million.

Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and diseases of the eye. Its products include Rhopressa and Roclatan.